paba/neoplasms

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. national phase application filed under 35 U.S.C. .sctn. 371 of International Patent Application No. PCT/PL2017/000018 filed Mar. 3, 2017, which in turn claims priority of Polish Patent Application No. P.416395, filed Mar. 4, 2016,

BACKGROUND OF THE INVENTION The present invention relates to a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of central nerve or tumor, which comprises administering to a patient

FIELD OF THE INVENTION The present invention relates to the inhibition of melanogenesis with para-aminobenzoic acid (PABA) and its use in treating melanotic cancer. BACKGROUND OF THE INVENTION Melanoma The incidence of melanoma in most developed countries has risen faster, over the past 50 years,

BACKGROUND OF THE INVENTION The present invention relates to a method of inhibiting tumor growth in a patient suffering therefrom and a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of

BACKGROUND OF THE INVENTION The present invention relates to a method of inhibiting tumor growth in a patient suffering therefrom and a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of

BACKGROUND OF THE INVENTION The present invention relates to a method of inhibiting tumor growth in a patient suffering therefrom and a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of

BACKGROUND OF THE INVENTION The present invention relates to a method of inhibiting tumor growth in a patient suffering therefrom and a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of

INTRODUCTION The present invention relates to novel peptidomimetics and other compounds which are useful as inhibitors of p21ras farnesyltransferase and as anti-cancer drugs. Farnesylation is required for the cancer causing activity of the oncogene product p21ras. Hence there is considerable

BACKGROUND OF THE INVENTION A number of short peptides with significant activity as inhibitors of cell growth have been isolated from the Indian Ocean sea hare Dolabella auricularia (Bai, et al., Biochem. Pharmacology 40: 1859-1864 (1990); Beckwith et al., J. Natl. Cancer Inst. 85: 483-488 (1993)